Amyloid Immunotherapy Vaccines for Alzheimer's Disease

Amyloid Immunotherapy Vaccines for Alzheimer's Disease

Pathway Diagram

Introduction

Amyloid Immunotherapy Vaccines for Alzheimer's Disease

Pathway Diagram

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Amyloid Immunotherapy Vaccines for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Immunotherapy / Disease-Modifying</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Amyloid-beta plaques and oligomers</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Cerebral Amyloid Angiopathy</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Subcutaneous/intramuscular injection (active); intravenous infusion (passive)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>FDA approved ([Lecanemab](/entities/lecanemab), [Donanemab](/entities/donanemab), Aducanumab); Clinical trials (others)</td>
</tr>
<tr>
<td class="label">Vaccine</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">ACI-35.40</td>
<td>AC Immune/Janssen</td>
</tr>
<tr>
<td class="label">ABvac40</td>
<td>Araclón Biotech</td>
</tr>
<tr>
<td class="label">CAD106</td>
<td>Novartis/Cytos</td>
</tr>
<tr>
<td class="label">ACC-001</td>
<td>Janssen</td>
</tr>
<tr>
<td class="label">UB-311</td>
<td>United Neuroscience</td>
</tr>
<tr>
<td class="label">ACI-24</td>
<td>AC Immune</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Solanezumab</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">ApoE4 status</td>
<td>Predicts ARIA risk, treatment response</td>
</tr>
<tr>
<td class="label">Baseline amyloid burden</td>
<td>Extent of plaque removal</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Disease progression marker</td>
</tr>
<tr>
<td class="label">[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)</td>
<td>Treatment response</td>
</tr>
</table>

Amyloid immunotherapy aims to stimulate the immune system to clear [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaques from the brain. Amyloid vaccines represent a disease-modifying approach targeting the fundamental pathology of Alzheimer's disease. This therapeutic strategy has evolved significantly over the past two decades, with multiple active vaccines and monoclonal antibodies in development and clinical use.

Overview

Mechanism of Action

Amyloid vaccines work by stimulating antibody production against [Aβ](/proteins/amyloid-beta)[@van2023]. The therapeutic approach leverages the immune system to target and clear the pathological amyloid deposits that accumulate in the brains of Alzheimer's disease patients.

Active Immunization

Active immunization involves administering the Aβ antigen itself, along with an adjuvant to stimulate the immune system:

• ANTIGEN: Aβ peptides (full-length Aβ1-40/42 or specific fragments)
• ADJUVANT: Stimulates immune response (e.g., QS-21, monophosphoryl lipid A/MPL)
• ANTIBODY RESPONSE: Patient's immune system generates anti-Aβ antibodies
• PLAQUE CLEARANCE: Antibodies cross the [blood-brain barrier](/entities/blood-brain-barrier), bind plaques, and promote microglial-mediated phagocytosis

• Long-lasting immunity after series of vaccinations
• Lower cost than passive immunization
• Potential for disease prevention in at-risk individuals

• Variable antibody response between individuals
• Risk of autoimmune encephalitis (observed in AN1792 trial)
• T-cell mediated inflammation concerns

Passive Immunization

Passive immunization involves administering pre-generated monoclonal antibodies directly:

• ANTIBODY ADMINISTRATION: Intravenous infusion of anti-Aβ antibodies
• TARGETING: Various epitopes (N-terminal, mid-region, C-terminal, protofibrils)
• ADVANTAGE: Controlled dosing, predictable pharmacokinetics, no autoimmune risk

• Lecanemab: Targets Aβ protofibrils (highest affinity)
• Donanemab: Targets N3pG (pyroglutamate) Aβ plaques
• Aducanumab: Targets conformational epitopes on Aβ plaques

Amyloid-Related Imaging Abnormalities (ARIA)

ARIA is the primary safety concern with amyloid immunotherapy:

ARIA-E (Edema):

• Brain edema or sulcal effusions
• Symptoms: Headache, confusion, visual disturbances
• Frequency: 12-24% of patients
• Management: MRI monitoring, dose suspension

• Cerebral microhemorrhages, hemosiderosis
• Frequency: 10-17% of patients
• Risk factors: ApoE4 carrier status, anticoagulation

Clinical Candidates

Active Vaccines (Active Immunization)

Passive Immunotherapy (Monoclonal Antibodies)

Clinical Trial Results

Lecanemab (Leqembi)

• Trial: CLARITY-AD (NCT03887455)
• Population: Early AD (MCI due to AD, mild AD dementia)
• Design: 18-month, randomized, double-blind, placebo-controlled
• Primary Outcome: Change in CDR-SB
• Results: 27% slower cognitive decline ( treatment effect: -0.45 CDR-SB)[@van2023]
• Amyloid Reduction: Mean centiloid reduction of ~55 at 18 months
• [Tau](/proteins/tau) Effects: Slowed tau accumulation on PET
• Safety: ARIA-E in 12.6%, ARIA-H in 17.3%

Donanemab (Kisunla)

• Trial: TRAILBLAZER-ALZ 2 (NCT04437511)
• Population: Early AD with low-to-medium tau
• Design: 18-month, randomized, double-blind, placebo-controlled
• Primary Outcome: Change in iADRS
• Results: 35% slower cognitive decline ( treatment effect: -3.25 iADRS)[@sims2023]
• Amyloid Reduction: 75% of patients achieved amyloid clearance
• Tau Effects: Reduced tau spread
• Safety: ARIA-E in 24% of patients, 3 deaths related to ARIA

Aducanumab (Aduhelm)

• Trials: ENGAGE and EMERGE (NCT02477800, NCT02484547)
• Population: Early AD
• Results: Mixed - EMERGE showed benefit at high dose, ENGAGE did not[@budd2022]
• Amyloid Reduction: Dose-dependent plaque reduction
• Controversy: Accelerated FDA approval 2021, controversy over efficacy
• Status: Withdrawn from market 2024

Gantenerumab

• Trials: GRADUATE I and II (NCT03444870, NCT03444883)
• Population: Early AD
• Results: Did not meet primary endpoints[@mintun2021]
• Dose: High subcutaneous doses
• Status: Development discontinued

Patient Selection and Biomarkers

Eligibility Criteria

Amyloid Confirmation:

• Positive amyloid PET scan (Centiloid ≥30)
• Reduced CSF Aβ42 or elevated Aβ42/Aβ40 ratio

• Preclinical AD (for prevention trials)
• MCI due to AD
• Mild AD dementia

• Low, medium, or high tau burden affects response
• Donanemab approved for low-medium tau patients

Predictive Biomarkers

Combination Approaches

Rationale for Combination Therapy

Amyloid-targeting therapies may be combined with:

• Anti-tau therapies: Address tau pathology simultaneously
• Neuroprotective agents: Enhance neuronal resilience
• Symptomatic treatments: Optimize cognitive function

Active Clinical Trials

• Lecanemab + Anti-tau: Multiple tau-targeted antibodies in development
• Lecanemab + Leuprolide: Phase 2 (completed)
• Amyloid + Neuroinflammation: Anti-inflammatory approaches

Future Directions

Prevention Trials

• [DIAN](/entities/dian-study): Dominantly inherited AD prevention
• A4 Study: Anti-amyloid treatment in preclinical AD
• Generation Programs: Prevention initiatives

Next-Generation Vaccines

• DNA vaccines: Encoding Aβ for sustained antibody production
• Viral vector vaccines: AAV-delivered Aβ immunogens
• Multi-target vaccines: Aβ + tau combination
• Personalized approaches: Based on genetic risk

Novel Antibody Formats

• Bispecific antibodies: Simultaneous Aβ targeting and immune engagement
• Engineered Fc: Enhanced microglial activation
• Brain-penetrant antibodies: Improved CNS delivery

See Also

• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)
• [Aducanumab](/therapeutics/aducanumab)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [Amyloid-Related Imaging Abnormalities (ARIA)](/diseases/amyloid-related-imaging-abnormalities-aria)

External Links

• [ClinicalTrials.gov - Amyloid Immunotherapy](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=amyloid+immunotherapy)
• [Alzheimer's Association - Treatment Options](https://www.alz.org/)
• [Lecanemab CLARITY-AD Results](https://www.nejm.org/doi/full/10.1056/NEJMoa2212948)
• [Donanemab TRAILBLAZER-ALZ 2 Results](https://jamanetwork.com/journals/jama/fullarticle/2807537)

Background

The study of Amyloid Immunotherapy Vaccines For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Amyloid Immunotherapy Vaccines for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: